Delivering Control

PolyPid empowers surgeons with greater control over surgical site care, gives patients confidence throughout their recovery, and delivers drug delivery precision that modern therapies require.

By integrating deep clinical insight with advanced drug-delivery science, we are redefining how healing is protected, placing control exactly where it matters most.

Care-Changing Outcomes

The Kynatrix™ platform eliminates burst and fluctuating drug release, enables delivery of a broad range of active pharmaceutical ingredients (APIs), including small molecules, cytotoxic agents, biologics, nucleic acids, and peptides.

Release durations can be customized, spanning several days to several weeks, thereby enhancing and extending therapeutic effectiveness.

Platform Highlights

Zero-Burst Release

No initial drug spike.

Customizable Duration

Tunable from several days to several weeks.

Layered Matrix Architecture

Controlled sequential disintegration.

Scalable Manufacturing Process

Designed for consistent quality and commercial-scale production.

Minimal Systemic Exposure

Reduced toxicity and side effects.

Substance Versatility

Suitable for antibiotics, cytotoxic agents, peptides, nucleic acids, and more.

Current Pipeline

Therapeutic Area

Product name

Pre-Clinical

Phase 1

Phase 2

Phase 3

Regulatory Review

In-house / partnership

SSI

D-PLEX₁₀₀

Indicated for prevention of surgical site infections (SSIs) following abdominal colorectal surgery. PDUFA date expected early 2027

In-house

Metabolic 
Disease

PP03A

Ultra-long GLP-1 Receptor Agonist designed for +50 days of linear release, maintaining effective blood concentrations without the peaks and troughs of currently available treatments.

In-house

Oncology

PP04A

Controlled and prolonged intratumoral delivery of a STING agonist, developed in collaboration with Immunogenesis.

Scientific Publications

View All Publications

Efficacy of a Novel Local Prolonged-Release Incisional Doxycycline on Surgical Site Infection Prophylaxis in Abdominal Colorectal Surgery: The SHIELD II Phase 3 Randomized Clinical Trial

Full article

Effect of local prolonged-release incisional doxycycline on surgical site infection prophylaxis in abdominal colorectal surgery: the SHIELD 1 randomized clinical trial

Full article

Impact of Locally Applied Doxycycline-Eluting Drug (D-PLEX) on Incisional Infection Rate in Elective Colorectal Surgery: A Phase 3, Prospective, Randomized, Double-Blind, Multicenter and Multinational Clinical Trial

Full article

Delivering Control

Care-Changing Outcomes

Platform Highlights

Current Pipeline

Scientific Publications

Contact Us